Skip to main content
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 2026 May 27;123(22):e2604770123. doi: 10.1073/pnas.2604770123

Transition-state analysis of the arginine-specific human ADP-ribosyltransferase 1

Daniel P Groom a, Jennifer T Aguilan b, Amanda Lopacinski a, Scott J Garforth a, Vern L Schramm a,1
PMCID: PMC13229280  PMID: 42201951

Significance

Dysregulation of hsART1 activity has been shown to permit immune cell evasion in non–small cell lung cancer through elevated mono-ADP ribosylation (MARylation) at Arg125 of purinergic type 2 receptor (P2X7) in P2X7-positive T cells, resulting in NAD+-induced cell death of tumor-penetrating immune cells. The transition-state structure of the human arginine-specific ADP-ribosyltransferase 1 (hsART1) is critical to understanding the enzymatic chemistry of this membrane-associated, mono-ADP-ribosyltransferase selective for MARylation of L-arginine residues. Here, we use kinetic isotope effects and computational chemistry to resolve the transition-state structure. Here, we use kinetic isotope effects and computational chemistry to resolve the transition-state structure for L-arginine-specific ADP-ribosylation catalyzed by hsART1. The information informs on chemistry and provides an important step toward the design of transition-state analogs.

Keywords: transition state, kinetic isotope effects, ADP-ribosylation

Abstract

The ADP-ribosylation of proteins is a versatile, reversible, posttranslational modification involved in the dynamic regulation of numerous cellular processes. Human ADP-ribosyltransferase 1 (hsART1, EC: 2.4.2.31) is a membrane-associated, GPI-anchored, mono-ADP-ribosyltransferase selective for mono-ADP ribosylation (MARylation) of L-arginine residues. Dysregulation of hsART1 activity has been shown to permit immune cell evasion in non–small cell lung cancer (NSCLC) through elevated MARylation at Arg125 of the purinergic type 2 receptor (P2X7) in P2X7-positive T cells, resulting in NAD+-induced cell death (NICD) of tumor-penetrating immune cells. With hsART1 emerging as an immunotherapy target in select cancers, there is a need to develop small-molecule inhibitors. The transition state (TS) for the MARylation of P2X7 peptide was determined from kinetic isotope effect (KIE) measurements of 3H-, 14C-, 18O-, and 15N-labeled NAD+ substrates. Quantum mechanical (QM) calculations of the reaction coordinate, mapped with experimental KIEs, identify a TS geometry consistent with a highly dissociative, asymmetric, concerted mechanism with minimal contributions from the leaving group nicotinamide (NAM) and minor contributions from the incoming L-arginine guanidinium. The absence of a normal deuterium solvent isotope effect identifies a positively charged guanidinium nucleophile, leading to a dication N-ribosyltransferase mechanism. Together with the unusual, normal 18O–O4′ KIE, we identified unique charge accumulation across the oxocarbenium at the TS caused by an increased bond order between the C1′–C2′, and decreased bond order between the C4′–O4′ of the nicotinamide mononucleotide ribose. This is the first L-arginine-specific ADP-ribosylation TS to be characterized, a step toward the design of TS analogs.


ADP-ribosylation is a reversible posttranslational modification where ADP-ribose (ADPR) from β-nicotinamide adenine dinucleotide (NAD+) is installed on the target substrate (1). While traditionally studied in the context of proteins, this modification is also installed on a diverse array of biomolecules, including nucleic acids and select small-molecule metabolites (2–4). The ADP-ribosylation of proteins is involved in the coordination of cellular processes, encompassing cellular signaling, stress-related responses, signposting DNA damage, and aiding in protein recruitment for its subsequent repair (5). These processes are regulated by the complementary activities of ADP-ribosyltransferases (ARTs) that install the ADPR, and are removed by specific ADPR glycosylhydrolases that work together to dynamically modulate ADP-ribosylation mediated effects (6–8).

ADP-ribosylation is also leveraged by various bacterial toxins to dysregulate normal cellular function during infection (1, 2, 9). While bacterial ARTs were originally defined as virulence factors targeting eukaryotic hosts, they are now recognized for broader ecological roles in mediating interbacterial competition (10–12) and defense against bacteriophage infection (13, 14).

ADP-ribosylation can occur by the installation of a single ADPR onto a protein surface residue (mono-ADP-ribosylation; MARylation) or through the sequential addition of multiple ADPRs to preestablished ADPR modifications to form long and branched polymers, called (poly-ADP-ribosylation; PARylation) (15). Both MARylation and PARylation have been shown to modulate target function (16–18). While ADP-ribosylation has been observed in vitro and documented in vivo across a variety of residues, arginine-specific MARylation is catalyzed exclusively by members of the ADP-ribosyltransferase C (ARTC) family (1, 19, 20). Of the four ARTCs expressed in humans, there are two catalytically active MARylating ARTCs (hsART1 and hsART5) and two catalytically inactive homologs that lack catalytic glutamates within the conserved R-S-E motif present within arginine-specific ARTCs (hsART3 and hsART4) (21, 22).

hsART1 is a membrane-associated glycosylphosphatidylinositol (GPI)–anchored enzyme that accumulates both intracellularly and extracellularly during maturation and trafficking (18). The exact intra- and extracellular partitioning of hsART1 varies between cell types, tissues, and cancer models. The nascent protein initially localizes to the endoplasmic reticulum (ER) before being transported to the plasma membrane and exported to the cell surface, allowing it to MARylate a diverse range of targets across both compartments (16–18, 24, 25).

hsART1 catalyzes the MARylation of several cellular protein targets and a weak promiscuous NAD+ hydrolase activity (Fig. 1A) (18, 23, 26). Targets of arginine-specific hsART1 include the P2X7 receptor (P2X7) (27). P2X7 is a purinergic type 2 receptor family, adenosine 5′-triphosphate (ATP)–gated cation channel involved in the activation of numerous proinflammatory pathways, as well as being essential for inflammatory responses and antitumor immunity in select T cell lineages (27, 28). hsART1 catalyzed MARylation of P2X7 at Arg125 proximal to the ATP binding pocket leads to constitutive activation (Fig. 1 B and C) (26). Overactivation of MARylated P2X7 triggers large pore formation, uncontrolled calcium influx, and phosphatidylserine efflux (26, 29). Together, the destabilization of the cell membrane and significant osmotic pressure lead to cell death through a process called NAD+-induced cell death (NICD; Fig. 1B) (30–32). While typically, extracellular NAD+ concentrations are low, within the tumor microenvironment, extracellular NAD+ concentrations can fluctuate and become significantly elevated due to cellular stress or death (33–35).

Fig. 1.

Five-panel figure: chemical reactions, cell mechanism diagram, molecular structures, kinetic graph, and labeled N A D plus structure.

(A) hsART1 is an arginine-specific ARTC that catalyzes both the MARylation of cellular protein targets and, in the absence of transferase substrate, weak NAD+ hydrolysis (23). (B) Extracellular hsART1 expressing cancers induce NAD+-induced cell death (NICD), in tumor-microenvironment recruited P2X7+ expressing CD8+ T cells. MARylation leads to activation of the P2X7, leading to rapid influx of extracellular calcium (B1). Activation leads to pore-formation (B2), and phosphatidylserine accumulation to the outer leaflet (B3). (C) AlphaFold 3 model of the hsART1:NAD+:hsP2X7 complex, hsART1 colored in red, hsP2X7 homotrimer colored in green, and NAD+ is colored in white. (Left) hsART1 binds to a single hsP2X7 monomer, and R125 MARylation site is bound within the hsART1 active site (Boxed). (Center) The NAD+hsART1 binding pocket with surrounding contacting residues, including hsP2X7 R125 (Green). (Right) hsART1:hsP2X7 protein interface at the transferase reaction center. Details of the plDDT scoring of the reaction center are provided in SI Appendix, Fig. S1. (D) Kinetic characterization of hsART1 catalyzed MARylation of the P2X7 peptide by coupled luminescence assay. Kinetic parameters are summarized in Table 1. Data points and error bars represent mean ± SD, and solid lines represent either fitting to SI Appendix, Eq. S1. (E) Structure of NAD+ indicating positions in the molecule which were isotopically radiolabeled with 3H, 14C 15N, or 18O.

In non–small cell lung cancer (NSCLC), high levels of hsART1 expression were associated with reduced tumor infiltration of P2X7-positive T cells, driven by P27XR MARylation and NICD axis (28, 36). Inhibition of hsART1, therefore, offers the unique avenue of immunotherapy, targeting extracellular MARylation as a mechanism to assist T cell–mediated tumor rejection (28). Elevated hsART1 expression has also been associated with poor prognosis in colorectal cancer (37), glioblastoma (38), and various gastric cancers (39), leading to potentially broader relevance in other cancer models.

Knowledge of the transition-state (TS) structure of an enzyme-catalyzed reaction provides a framework for the rational design of tight-binding transition-state analogs (TSA). The measurement of intrinsic kinetic isotope effects (KIEs) provides the only experimental method to deliver subbond order resolution of the TS structure, including its bond distances, angles, and charges.

The mechanisms of the weak, nonspecific NAD+ glycohydrolase activity of cholera toxin subunit A (CTA, the ARTC namesake homolog) (40), pertussis toxin subunit A (PTA) (41), and diphtheria toxin fragment A (DTA) (42) have been studied by KIE, and the TS structures have been proposed. Of the three TS-characterized classes of ADP-ribosylating exotoxins, only the TS of the native ADP-ribosylation for PTA (43, 44) and DTA (45) have been studied with peptide or protein substrates. Across the ADP-ribosylating exotoxins, both the hydrolytic and transferase TSs are characterized by nearly completely dissociated nicotinamide (NAM) groups, only minimal interaction of the incoming nucleophile, and with a pronounced oxocarbenium characteristic (40–45). The canonical L-arginine specific MARylation catalyzed by the CTA was inaccessible due to the high substrate Km for NAD+ and modestly slow turnover (40, 46).

In this study, we establish the first TS structure of L-arginine specific MARylation catalyzed by ARTCs through the measurement of the intrinsic KIEs for the MARylation of a P2X7 peptide analog by hsART1 (Fig. 1A–C). Together with computational exploration of the reaction coordinate, mapped with in silico KIEs, we can establish the TS structure by comparison to experimentally measured KIE values. This provides the first TS structure for an arginine-dependent ART. The TS structure and its electrostatic potential surface (ESPS) give insight into arginine-specific MARylation and provide information for the design of TSAs.

Results and Discussion

hsART1 MARylates P2X7 Peptide.

In vivo MARylation of P2X7 at R125 by hsART1 leads to constitutive activation of the receptor and ultimately NICD (Fig. 1B) (30–32). The ADP-ribosylation of P2X7 by hsART1 was modeled with a peptide spanning the flanking five amino acids surrounding the canonical in vivo MARylation site, R125, P2X7(120−130), hereby referred to as P2X7 peptide. The wild-type P2X7 sequence contains two adjacent arginines, R125 and R126, a previously reported motif for in vivo ART specificity (47). The substrate specificity for MARylation of the P2X7 peptide was monitored by HPLC and LC-MS against the wild type sequence as well as peptides where arginines were replaced by glycines at either (or both) R125 and R126 positions, P2X7(R125G), P2X7(R126G), P2X7(R125G/R126G) (SI Appendix, Figs. S2 A and B and S3). hsART1 can MARylate P2X7 peptide, in preference to P2X7(R125G) or P2X7(R126G) variants (Table 1). hsART1 can MARylate R126, but has a weaker substrate preference than for the native R125 site. hsART1 is unable to MARylate P2X7(R125G,R126G) peptide that lacks both arginine sites (SI Appendix, Fig. S2).

Table 1.

Steady-state kinetic constants for hsART1 for MARylation of P2X7 peptides

Peptide Sequence kcat (s−1) Km (mM) kcat/Km (M−1 s−1)
wt PEYPTRRTLCS 11.1±0.3 0.103±0.010 1.08±0.11×105
R125G PEYPTGRTLCS 10.2±0.3 0.344±0.029 2.96±0.27×104
R126G PEYPTRGTLCS 9.19±0.29 0.186±0.017 4.93±0.49×104

Kinetic constants were acquired from fitting to SI Appendix, Eq. S1. Assays were performed at 1 mM NAD+, various concentrations of peptide (0.0219 to 0.7 mM) initiated with the addition of hsART1.

Steady-state kinetic constants were determined for the MARylation of the P2X7 peptides from initial rates following MARylated-peptide formation using a luminescence-coupled assay (Table 1 and SI Appendix, Fig. S2C). hsART1 MARylation rates of P2X7 peptides are comparable to those of previously reported L-arginine analogs, with kcat ranging between 11.1 ± 0.3 and 9.19 ± 0.29 s−1. We observed comparable Km values for R125 containing peptides increasing from 0.103 ± 0.010 to 0.186 ± 0.017 mM for P2X7 and P2X7(R126G), respectively, with a further increase in Km for P2X7(R125G) to 0.344 ± 0.029 mM for the noncanonical MARylation R126 site. hsART1 shows 10-fold improved substrate specificity, (kcat/Km) for the wild-type P2X7 peptide compared to previously characterized L-arginine analogs (23). Peptide fragmentation was performed on the P2X7 peptides (SI Appendix, Fig. S3). For the wild-type peptide under nonsaturating NAD+ concentrations, we observed competition for MARylation between both R125 and R126 sites at partial turnover (SI Appendix, Fig. S3C). We observed no catalytic processivity and no double MARylation at both R125 and R126 sites. The lack of selectivity for specifically R125 is not surprising, given the small two- to threefold change in kcat/Km relative to the single glycine-substituted peptides (SI Appendix, Fig. S2C and Table 1). The lack of processivity prevents interference with KIE measurements; therefore, KIEs were performed on the wild-type sequence peptide as the RR-motif is the as a preferred substrate in vitro, and in vivo (47).

hsART1 Shows Modest Commitment to Catalysis In Vitro.

KIEs determined by intermolecular competition manifest on V/K and report isotopic discrimination on the rate-limiting steps up to, and including, the first irreversible step of the reaction. This encompasses both chemistry, which is reported on by the intrinsic KIE, KIEint, and substrate binding. Only the KIEint can be interpreted to map the TS structure with the potential contributions of substrate binding masking KIEint and thus must be experimentally established.

The forward commitment (Cf) reflects the probability of the trapped substrate:enzyme Michaelis complex to proceed through catalysis relative to the dissociation back to free substrate and can be used to correct the experimentally observed KIE, KIEobs, to the KIEint. Arginine-specific MARylation is chemically stable and irreversible, making reverse commitment (Cr) unlikely for the hsART1 catalyzed reverse reaction over the experimental window (19, 48, 49).

MARylation of the P2X7 peptide was measured by the isotope trapping method (50). Forward commitment was determined by rapidly mixing hsART1 with [HA1′–3H]NAD+ to form the hsART1:NAD+ binary complex, followed by a rapid dilution with excess unlabeled NAD+ and P2X7 peptide. Analysis of the amount of substrate within the binary complex that is released or that is converted to product yielded a forward commitment factor of 0.106 ± 0.005 (SI Appendix, Fig. S4). The observed modest Cf results in a small correction to the KIEobs to obtain the KIEint (Eq. 1).

KIEint=KIEobs1+Cf−Cf. [1]

Measurement of Intrinsic KIEs for hsART1 MARylation.

Primary and secondary KIEs at isotopically sensitive positions on the nicotinamide mononucleotide (NMN) moiety of NAD+ for MARylation of the P2X7 peptide were measured by intermolecular competition using radiolabeled NAD+ (Fig. 2 and Table 2). The KIEs were determined by the change in the isotope ratios traced by 3H and 14C, comparing the accumulation of radiolabel on the MARylated P2X7 product at partial and complete conversion using Eq. 2,

KIEobs=ln(1−f)ln1−fRfR0, [2]

Fig. 2.

Diagram of P 2 X 7 Peptide interaction. Distances d 1 and d 2 are labeled. Six isotopic values with plus or minus error margins are provided.

Intrinsic KIEs and TS bonds for hsART1-catalyzed MARylation of P2X7 peptide. [CA1′–14C] on NAD+ are remote, control labels (KIE = 1.000). Bond distances d1 and d2 are the initial bond distances scanned to generate the primary KIE landscapes (Fig. 4).

Table 2.

Intrinsic and calculated KIEs for the MARylation of P2X7 peptide catalyzed by hsART1

Label Type of KIE Intrinsic KIE∗ TS1 KIEcalc† Final TS KIEcalc‡
[CN1′–14C]NAD+ Primary—14C 1.039±0.003(3) 1.038 1.041
[NN1–15N,CA1′–14C]NAD+ Primary—15N 1.028±0.002(3) 1.028 1.027
[HN1′–3H]NAD+ α-Secondary—3H 1.174±0.010(4) 1.165 1.168
[ON4′–18O,CA1′–14C]NAD+ α-Secondary—18O 1.012±0.005(7) 0.995 1.006
[HN2′–2H,CA1′–14C]NAD+ β-Secondary—2H 1.104±0.002(3) 1.098 1.107
[HA1′–3H]NAD+ Remote—3H 1.002±0.003(3) N.D N.D

∗Experimental KIEs have been previously corrected to 0% substrate depletion using Eq. 2. Intrinsic KIEs were obtained by correction for forward commitment factor (Cf = 0.106 ± 0.005; SI Appendix, Fig. S4 using Eq. 1). Number denotes the number of independent experiments.

†Theoretical KIEs were determined on the intermediate TS (TS1, d(1′C-NAM) = 2.68 Å, d(1′C-Gu) = 2.22 Å).

‡Final TS (d(1′C-NAM) = 2.68 Å, d(1′C-Gu) = 2.18 Å) using B3LYP/6-31G* calculations using the 6-31+G(d,p) basis set (Materials and Methods and SI Appendix); remote 1′-AMP positions are used only as remote labels and were not included in the analysis.

where f is the fraction of substrate conversion, and R corresponds to the ratios 3H/14C ratios for the partial (20%, Rf) and complete (100%, R0) conversion.

After correction for the forward commitment (Eq. 1), the observed KIEs are corrected to reflect the intrinsic KIEs, KIEint.

The isotope effect for [CA1′–14C] is remote from the reaction center and assigned as unity, but the binding isotope effects (BIEs) of hydrogen at remote positions can influence the measurement of competitive KIEs on V/K. The KIE for the remote position [HA1′–3H] was measured and found to be unity (1.002 ± 0.003), therefore, where [HA1′–3H]NAD+ is utilized as a light isotope competitive reporter, the experimentally measured KIE is representative of the true observed KIE.

The KIE for the C1′ anomeric carbon is sensitive to the contributions from both the leaving group (NAM) and the incoming nucleophile (guanidinium) at the TS during N-ribosyl transfer. The significant primary KIE for the [CN1′–14C] position, 1.039 ± 0.003, together with the large [NN1-15N], 1.028 ± 0.002, indicates an asymmetric TS with modest contributions of the incoming nucleophile while the pronounced [NN1-15N] is consistent with almost complete dissociation of the leaving group at the TS and loss of the C1′–N1 bond order.

The modest [HN1′–3H] α-secondary KIE, 1.174 ± 0.010, is consistent with weak residual bond order to C1′ and substantial but incomplete sp3 to sp2 rehybridization at the TS. The β-secondary [HN2′–2H] KIE, 1.104 ± 0.002, is highly sensitive to the H2′–C2′–C1′–N1 dihedral and reports on the degree of the hyperconjugation between the C2′–H2′σ-bond and the 2pz orbital of the C1′ at the TS (51).

We determined a normal KIE for [ON4′–18O] of 1.012 ± 0.005 (established in 7 independent measurements, across 2 separately synthesized batches of [ON4′–18O, CA1′–14C]NAD+). Generally, inverse isotope effects for 4′–18O near 0.98 have been reported for other N-ribosyl hydrolases (42), transferases (52), and uncatalyzed hydrolysis (53). The normal 4-18O KIE indicates a decrease in the O4′ bond order at the TS, and is unique to L-arginine-specific MARylation.

Solvent Isotope Effect.

1,N6-ethenoadenine dinucleotide (ϵ-NAD+) is a fluorescent dinucleotide derivative of NAD+ and substrate analog for hsART1 that contains a fluorescent ethenoadenine base that is quenched in free solution by the NAM within the dinucleotide (23, 54). Cleavage of NAM permits the direct measurement of the fluorescent ϵ-ADPR product and allows for a direct measurement of MARylation (23). Initial reaction rates for the MARylation of P2X7 peptide were measured at variable concentrations of either ϵ-NAD+ or peptide in under near saturating concentrations of the secondary substrate in water or 80% D2O (v/v) (Fig. 3). Corrections for viscosity changes at 80% D2O, reaction rates were made by comparison to a 5% glycerol control (Fig. 3, Right and SI Appendix, Fig. S5) (55). Assays were performed at pH 8.0, where there is a well-defined plateau for both kinetic constants, V and V/K, to accommodate shifts in the pKA that may be misinterpreted SKIEs (23, 56). With ϵ-NAD+ as the variable substrate, no SKIEs were observed on V or V/K. With the P2X7 peptide as the variable substrate, a small inverse SKIE was observed on V/K, 0.61 ± 0.05 (as fit by SI Appendix, Eq. S2), but this may be attributed to the effect of viscosity as independent fits V, and V/K are within the error of the fit compared to the glycerol control. Inverse SKIEs have been reported for CTA catalyzed NAD hydrolysis (40). Regardless, the absence of a normal SKIE for the hsART1 catalyzed MARylation indicates that there is no proton exchange at the TS. Therefore, any deprotonation that may occur with the attacking guanidinium happens before or afterMARylation.

Fig. 3.

Four-panel figure: line graphs of v sub 0 super app vs. concentration and bar graphs of V and V slash K vs. D sub 2 O fraction.

MARylation of P2X7 peptide by hsART1 has no observed SKIE for ϵ-NAD+ (Top) and a modest inverse SKIE for P2X7 peptide (Bottom). (Left) Initial rates for varying ϵ-NAD+ under saturating P2X7 peptide (Top) and varying P2X7 peptide under saturating ϵ-NAD+ (Bottom). Data points and error bars represent mean ± SD, and solid lines represent fitting to SI Appendix, Eq. S1. (Right) Kinetic constants from fitting independent rate curves using the Michaelis–Menten equation (SI Appendix, Eq. S1) for ϵ-NAD+ (Top) and P2X7 peptide (Bottom). SKIE for P2X7 peptide was fit using SI Appendix, Eq. S2.

Computationally Modeling the hsART1 MARylation TS.

The ground state for hsART1 catalyzed MARylation used a structural model of the active site generated from an AlphaFold 3 model of the hsART1:NAD+:P2X7 trimer ternary complex (57). The generated model placed the canonical R125 in vivo MARylation site presented in close proximity to the CN1′ of the NMN moiety of NAD+ (Fig. 1C and SI Appendix, Fig. S1).

From the large [NN1–15N] KIE (Table 2), and absent SKIE (Fig. 3), a late dissociative TS with little contribution from the departing NAM and modest contribution from the incoming guanidinium is established, with no assistance from acid–base chemistry at the attacking guanidinium is concerted with the TS. Thus, the L-arginine guanidine is likely to be protonated during the attack, with subsequent deprotonation of the product happening immediately after the transfer has occurred.

KIE landscapes are used to compare computed to intrinsic experimental KIEs values and thereby infer the TS structure. Computed KIEs for hsART1 used a ground state (GS) reaction model containing the side chains of E228, E230, R179, and S202 of the R-S-EXE motif of ARTC homologous enzymes. QM DFT and subsequent KIE calculations were performed varying the leaving group NAM d(CN1′–NN1) and attacking nucleophile guanidinium d(Nη1–CN1′) (Fig. 4 and SI Appendix, Fig. S6). Calculated and experimental primary [CN1′–14C] and [NN1-15N] isotope effects, as well as the α-secondary [HN1′–3H] KIE, converge within experimental error to give a late dissociative asymmetric TS structure with a weak bond order to the NAM leaving group, and modest bond order to the incoming nucleophile, characteristic of an DN+AN mechanism (Fig. 4A) However, these initial KIE landscapes (TS1 KIEcalcb; Table 2) failed to recapitulate the measured normal [ON4′–18O] KIE. The initial computed 18O KIE value, 0.995, is significantly smaller than the experimental value of 1.012 ± 0.005, but a value larger than measured 18O KIEs for other ribosyltransferases (Table 2 and SI Appendix, Fig. S6) (42, 52, 53).

Fig. 4.

A three-panel figure. Panel A: contour plots. Panel B: T S 1 structure. Panel C: graphs of K I E sub calc for super 14 C, super 3 H, and super 18 O.

Comparison of intrinsic and calculated KIE values as a function of leaving group NAM (C1′–N1) and attacking guanidinium nucleophile (Nη1-CN1′) bond distances across the reaction coordinate. (A) Overlapping KIE landscapes for over 0.1 Å(Left), and a subsection calculated over 0.01 Å(Right) for the primary KIEs for 1′–14C, 1–15N, and α-secondary 1′–3H, colored in red, green, and blue, respectively. The Right panel demonstrates the TS bond lengths in agreement with the 1–14C–CN1′ 1–15N–NN1, and 3H–HN1′ KIE values, with the overlap region highlighted in gold. The shaded regions represent the experimental value for each respective KIE with one SD. (B) Representative TS1 taken from the overlapping region of A, representing a feasible TS (2.68, CN1′–NN1 and 2.22, Nη1-CN1′, with a single imaginary frequency). (C) Representative QM DFT bond scans and computed KIEs of feasible TS taken from the overlapping region, varying the C1′–C2′ distance as a function of varying C1′–O4′ distances for the 1′–14C (Left), 1′–3H (Middle), and 4′–18O (Right). Points represent computed KIEs and the shaded area represents the experimental region (KIEint± SD).

Mapping the Unique Normal 4′–18O KIE.

The influence of the delocalized ribocation in relation to the measured normal [ON4′–18O] α-secondary KIE, was investigated by scans of the d(CN1′–ON4′), d(CN1′–CN2′), and d(CN4′–ON4′) bonds on a geometry within feasible TS structures (TS1; 2.68, CN1′–NN1 and 2.22, Nη1–CN1′, with a single imaginary frequency, Fig. 4B). Increasing the CN1′–ON4′ bond length decreased the oxocarbenium characteristic (Pauling Bond Order, BO; from 1.623 to 1.170) and increased the KIEcalc into the experimentally measured α-secondary 18O KIE range (Fig. 4C). This, however, caused an increase in the calculated primary [CN1′–14C] and [HN1′–3H] α-secondary KIEs (SI Appendix, Fig. S6). Elevation of these KIEs is inconsistent with converging on an SN1, or SN2-like mechanism, where as one of the KIEs is pulled toward unity, the other is increased (58, 59). Varying the CN1′–ON4′ bond as a function of the CN1′–CN2′ distance maintained the computed KIEs within the experimentally measured range when the ratio of the bond lengths was retained, but increased the β-secondary [HN2′–2H] KIE, and generated multiple imaginary frequencies when the CN1′–CN2′ was compressed (Fig. 4C and SI Appendix, Fig. S7). Decreasing the CN4′–ON4′ (BO: 0.819 to 0.693) and compression of the CN1′–CN2′ bond (1.143 BO at the TS) selectively increased the α-secondary 18O KIE, gave agreement between the experimental and computed KIEs (SI Appendix, Fig. S8). The final TS structure of hsART1-catalyzed MARylation satisfied all experimentally measured KIE values and exhibited a single imaginary frequency corresponding to ADP-ribosyl transfer (Fig. 5 and Table 2).

Fig. 5.

Two-panel figure compares G S and T S states of N A D super plus and N A M. Bond lengths change from 1.50 and 3.48 Angstrom to 2.68 and 2.18 Angstrom.

Comparison of electrostatic potential surface (ESPS) calculated for the GS, and the TS that satisfies all experimentally measured KIE. Blue coloring corresponds to a relative electron deficiency, while red defines a relative electron enrichment. The natural charges from NBO calculations for O4′, C1′, C2′, C4′, Nη1, Nη2, NE, and the summed charges for the NAM leaving group are annotated.

TS Bond Order and Charge Distribution.

A charge analysis of the TS relative to the GS gave a positively charged NAM partially delocalized to the anomeric C1′ and between the C1′–O4′, with a +0.255 natural charge on C1′ and partial oxocarbenium between the C1′–O4′ having an elevated BO of 1.131 (Fig. 5, SI Appendix, Fig. S9). As the C1′–N1′ bond is lost at the TS, electron density increases in the leaving NAM, with +0.387 natural charge at the C1′ anomeric carbon at the TS. The NAM is essentially neutral at the TS. At the TS, the ribocation O4′ increases in charge from −0.593 in the GS to −0.470 in the TS. Significant oxocarbenium character develops with a Pauling BO of 1.516 for the C1′–O4′ at the TS. The development of oxocarbenium-ribocation character is supported by the modest accumulation in electron density at CN4′, with partial loss of the CN4′–ON4′ bond. The delocalized ribocation is also uniquely characterized by the compression of the C1′–C2′ bond, leading to an increase in electron density and a decrease in charge at the C2′ position from 0.062 to −0.007 from the GS to the TS. The positive charge of the attacking guanidinium is delocalized across the Nη1 attacking nitrogen, Nη2, and NE. At the GS, there is electron enrichment at the E228 contact between the Nη2 and NE with a natural charge of −0.840, and −0.648, and electron deficiency on the Nη1, with a natural charge of −0.896. At the TS, there is an increase in electron deficiency in the attacking Nη1 to −0.848, the solvent-exposed proton increasing from 0.448 to 0.469. The electron deficiency across the E228 and Nη2, NE contact increase to −0.821 and −0.624, respectively.

Mutagenesis of E228 and E230.

E230 makes contact with the 2N′-hydroxyl of NMN and is essential for hsART1 activity in vitro, with mutation to glutamine completely abolishing activity (SI Appendix, Fig. S10). Homologous mutations of E230 to glutamine completely abolish both the MARylation and the weak promiscuous NAD+ hydrolase activities in ART homologs (60–64). Mutation of E228 to glutamine selectively reduces ART1 MARylation activity, but modest NAD+ hydrolase activity is retained, similar to other homologous mutations in arginine-dependent ARTs (SI Appendix, Fig. S10 and Table S1) (60–64). E230 facilitates an essential and unique charge at the TS where the generated charge is delocalized between the ON4′ and CN1′ but also partially with the CN2′ position of the NAD+.

Conclusions

Dysregulation of hsART1 function within the tumor microenvironment is emerging as a valid immunotherapy target by preventing tumors from killing CD8+ T cells via overactivation of P2X7 (28, 33–36). Experimental KIE measurements and DFT calculations permitted the determination of the first TS structure of L-arginine-specific MARylation. The lack of normal SKIEs, identified hsART1 achieves a distinct dication TS, where the incoming nucleophile guanidinium is protonated, attacking the positively charged NMN moiety. Previously characterized TS of MARylating toxins have a similar late dissociative TS but have attacking residue nucleophiles that are neutral or negatively charged, either a deprotonated histidine or cystine for the DTA (43, 44) or PTA (45), respectively. While unexpected, there is precedent for positively charged, protonated guanidinium of L-arginine acting as the preferred nucleophile across alternate reactions, including in select protein methylarginine transferases (PRMTs) (65, 66) and arginine-specific glycosyltransferases (GTs) (67). The absence of a normal SKIE in PRMT1, corroborated by QM/MM calculations, identified that arginine deprotonation occurs postmethyl transfer (65, 66). Similar to hsART1, PRMTs contain two glutamates that flank the guanidinium and provide sufficient activation for the protonated Nη1 of L-arginine to attack the incoming donor methyl from S-adenosyl-l-methionine (SAM) (65, 66, 68). The L-arginine-specific GT NleB and SseK have been suggested to proceed through an SNi like mechanism from structural work (69, 70). A recent QM/MM study on NleB1 supported a late dissociative mechanism that is stabilized by an oxocarbenium in the transferring sugar but identified that the attacking guanidinium is protonated during initial transfer (67). A single glutamate sits in plane with the attacking guanidinium and activates the nucleophile through contacting both the Nη1 and Nη2 (67, 70). While strictly not a dication reactant TS similar to arginine-specific hsART1 catalyzed MARylation or PRMT1 catalyzed methyl transfer, NleB-like GTs highlight that simultaneous activation of both Nη1 and Nη2 may be key for facilitating the protonated guanidinium nucleophile.

The intrinsic KIEs are consistent with a late dissociative, asymmetric DN+AN reaction mechanism with minimal contributions from the leaving group NAM, at 2.68 Å, and minor contributions from the incoming L-arginine guanidinium, at 2.18 Å, similar to previously characterized NAD+-dependent enzymes (Fig. 6). The positive charge of NAM within NAD+ is delocalized across the C1′ and C1′–O4′ bond, leading to a partial oxocarbenium characteristic in the GS. At the TS, the positive charge is further delocalized between the C1′–O4′, leading to an increase in the oxocarbenium characteristic. The resulting charge is, uniquely, stabilized across the C1′–C2′ bond by hsART1 E230 contacting the 2′-hydroxyl of the reactant, leading to compression of the bond with loss of bond order between the C4′–O4′ bond.

Fig. 6.

Graph of L G departure vs. nucleophile attack bond order. Points cluster at top-left D sub N + A sub N, far from the diagonal substrate-product line.

More O’Ferrall–Jencks plot showing the traditional reaction space for NAD+ (or NMN) N-glycoside hydrolysis or transfer for previously characterized enzymes, measured by KIE. The axes are the bond orders from C1′, the anomeric carbon, to the leaving group and the nucleophile. Bond orders in the reactant (Bottom Left) and products (Top Right) are shown. In a stepwise DN+AN (SN1) mechanism, an oxocarbenium ion intermediate is traditionally formed (Top Left) by dissociation of the leaving group. The nucleophile attacks C1′ in a separate step. A concerted, synchronous ANDN (SN2) mechanism would follow the dashed diagonal line. The selected experimental Pauling Bond orders are shown for NAD+ glycohydrolase CTA (40), PTA (41), and DTA (53), pyrophosphorylase activity of NAMPT (75), ADP-ribosylation of acetyllysine by Af2Sir2 (52), MARylation for PTA (43, 44), DTA (45), and hsART1 (this work).

Select N-ribosyltransferases and hydrolases have been proposed to proceed through an endocyclic mechanism where the C1′–O4′ is first broken prior to the cleavage of the C1′–N1 bond. This too would manifest as a normal 18O KIE; however, the absence of a normal SKIE also precluded this mechanism for hsART (58, 71–73).

Despite the mechanistic similarities between ARTCs and ARTDs, there lacks a tight-binding small molecule inhibitor for ARTCs, as seen in other ARTD family members such as PARPs (74). MARylation by the ARTD homolog, DTA has been previously characterized as having a completely dissociated NAM group and a pronounced oxocarbenium characteristic with an inverse α-secondary 18O (42, 45). Previous TSAs based on the late dissociative, oxocarbenium TS of MARylating exotoxins CTA, PTA, and DTA have only shown modest binding affinities in the low micromolar range (45). While hsART1 exhibits a similar late dissociative oxocarbenium TS, the present subangstrom geometry and unique electrostatics of the hsART1 TS will assist the design of mechanism-based TSA inhibitors for arginine-specific MARylation. The unique TS features, such as loss of bond order between C4′–O4′, as well as inclusion of an analogous fragment to the positive nucleophile mimicking the dication TS, can be leveraged to push binding potency higher for future TSAs.

Materials and Methods

Supplementary materials and methods are available in SI Appendix. These methods encompass a detailed breakdown of materials; synthesis and purification of all isotope-labeled intermediates and NAD+; the measurement of forward commitment for the hsART1:NAD+ binary complex; further computational details.

Synthesis of Isotopically Labeled NAD+ Substrates.

[HA1′–3H]NAD+ & [HN1′–3H]NAD+, and [CA1′–14C]NAD+ & [CN1′–14C]NAD+ were synthesized enzymatically from [1–3H]ribose, and [1–14C]ribose, respectively (American Radiolabeled Chemicals, Inc.). [ON4′–18O,CA1′–14C]NAD+ was synthesized from [5–18O]glucose (Omicron Biochemicals, Inc.) and [1′–14C]ribose. [HN2′–2H,CA1′–14C]NAD+ was synthesized from [2– 2H]ribose (Omicron Biochemicals, Inc.) and [1–14C]ribose. [NN1–15N,CA1′–14C]NAD+ was synthesized from [1–15N]NAM (Advanced Molecular Technologies) and [1–14C]ribose.

Detailed protocols for the synthesis of isotopically labeled NAD+ are available in SI Appendix, Methods S3 and Figs. S11–S15.

Commitment to Catalysis.

The forward commitment factor (Cf) to catalysis was measured by substrate trapping (50) using [HA1′–3H]NAD+ with a rapid mixing Quench Flow (RQF-3, KinTek). The formation of radiolabeled MARylated-P2X7 peptide was quantified after the pulse into excess unlabeled NAD+, and P2X7 peptide, first separating the starting material from product by HPLC and then quantifying by liquid scintillation counting (LSC) of the product compared to a rapidly mixed but unchased control. A detailed procedure is available in SI Appendix.

Kinetic Isotope Effect Measurements: Experimental KIEs.

KIEs were measured under competitive conditions using the isotope ratio method. The isotopically sensitive label of interest was mixed with the corresponding remote label; when 14C was the reporting label for the isotopically sensitive position, [HA1′–3H]NAD+ was used, and when 3H was the reporting label, [CA1′–14C]NAD+ was used. The 3H to 14C cpm ratio was equal, with no less than 2 × 105 cpm of 14C per experiment. Radiolabeled NAD+ was repurified by HPLC the day before use to remove any ADPR generated from degradation as outlined in SI Appendix.

The reaction mixture (0.5 mL) contained 50 mM HEPES (pH 8.0) and 0.1 mM NAD+ (including 3H and 14C labels) and 0.25 mM P2X7(120−130). The reaction was initiated by adding hsART1 to a final concentration of 5 nM, and 0.4 mL of the reaction was quenched with 0.5% TFA (final concentration) after 15–20% depletion of the substrate. The remaining 0.1 mL was driven to 100% competition with the addition of 50 nM hsART1; the reaction was then allowed to proceed for 60 min and quenched with TFA (0.5% final). Unreacted substrates and products were separated using reverse-phase HPLC as outlined in SI Appendix.

Four replicate injections were purified by RP-HPLC for both the partial and complete reactions (SI Appendix, section S2C). Peaks corresponding to the MARylated P2X7 peptide product were collected and dried overnight. The dried samples were redissolved in 200 μL of water and mixed with 10 mL of scintillation fluid (Ultima Gold, Revvity).

The 3H/14C ratios were measured by scintillation counting (5 min/cycle, 10 cycles; Tricarb 4910 TR Revvity). The channels 1 and 2 were set to encompass all 3H signal (>99.9%) in channel 1, with counts in channel 2 solely from 14C. After calibration of the ratio (r) between those two channels using ribose, ([1–14C]ribose, >1 × 105 cpm), the exact amount of 3H and 14C in each of the samples was determined using

cpm(3H)=cpmchannel1−cpmchannel2r, [3]
cpm(14C)=cpmchannel2(1+r). [4]

To correct the observed KIEs, KIEobvs, to 0% depletion of substrate, Eq. 2 was used. When the isotopic enrichment was <99%, observed KIEs were corrected using the following equation:

KIEobs=(KIEobs*−1+e)/e, [5]

where KIEobvs∗ is the apparent uncorrected observed KIE and e is the fractional isotope enrichment of the label at the isotopically sensitive position. When [HN2′–2H,CA1′–14C]NAD+ and [ON4′–18O,CA1′–14C]NAD+ were the heavy label, e was 0.980 and 0.903, respectively.

Solvent Deuterium Kinetic Isotope Effects.

To probe the rate-limiting nature of proton transfer steps, solvent deuterium KIEs (SKIE) on hsART1 catalyzed MARylation of P2X7 were determined using a fluorescent analog of NAD+, nicotinamide 1,N6-ethenoadenine dinucleotide (ϵ-NAD+) (23). A detailed summary of SKIEs performed with ϵ-NAD+ is available in SI Appendix.

Computationally Modeling the TS Structure.

For hsART1 catalyzed MARylation of P2X7 peptide, we followed the general procedures previously established for solving TS structures through quantum mechanical (QM) calculations and computational TS analysis. Detailed computational methods can be found in SI Appendix (59, 75, 76). All subsequent geometry optimizations and frequency calculations were performed with Gaussian 16 (77). In our final QM models, we simulated the GS using B3LYP functional and 6-31+G(d,p) basis set. The calculated vibrational frequencies were scaled by 0.9613 to reproduce the true vibrational zero-point energies for calculations of theoretical KIEs in the ISOEFF07 program at the experimental temperature (25 °C) (78, 79). ESPSs were calculated by using the CUBE program from Gaussian 16 (77) and visualized in Pymol 3.07 (80) (isovalue = 0.04). More details of the computational methods are available in SI Appendix.

Supplementary Material

Appendix 01 (PDF)

Acknowledgments

This work was supported by NIH Research Grant GM041916; P30 CA013330, which supports the Montefiore Einstein Comprehensive Cancer Center. Assistance was provided by the Einstein Macromolecular Therapeutics Development Facility for purification of hsART1, and hsART1 mutants, which is supported by the Montefiore Einstein Comprehensive Cancer Center. The Einstein Proteomics Lab gratefully acknowledges for funding the Hevolution Foundation (AFAR), the Einstein-Mount Sinai Diabetes Center, the ERC-CFAR Center for AIDS research, and the NIH Office of the Director (S10OD030286).

Author contributions

D.P.G., J.T.A, S.J.G., and V.L.S. designed research; D.P.G., J.T.A., and A.L. performed research; D.P.G. and J.T.A. analyzed data; and D.P.G., J.T.A. S.J.G, and V.L.S. wrote the paper.

Competing interests

The authors declare no competing interest.

Footnotes

Reviewers: G.J.D., University of York; D.V.F., Universiteit Leiden Leids Instituut voor Chemisch Onderzoek; J.C.W., McMaster University Department of Biochemistry & Biomedical Sciences; and S.G.W., University of British Columbia.

Data, Materials, and Software Availability

Accession Codes: hsART1 (UniProt: P52961) (81), hsP2X7 (Uniprot: Q99572) (82), hsARH1 (UniProt: P54922) (83), hsNUDIX5 (UniProt: Q9UKK9) (84), and CsPPDK (UniProt: P22983) (85). All other data are included in the manuscript and/or SI Appendix.

Supporting Information

References

  • 1.Lüscher B., et al. , ADP-ribosyltransferases, an update on function and nomenclature. FEBS J. 289, 7399–7410 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Schuller M., et al. , Molecular basis for the reversible ADP-ribosylation of guanosine bases. Mol. Cell 83, 2303–2315.e6 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Baysarowich J., et al. , Rifamycin antibiotic resistance by ADP-ribosylation: Structure and diversity of Arr. Proc. Natl. Acad. Sci. U.S.A. 105, 4886–4891 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wolfram-Schauerte M., et al. , A viral ADP-ribosyltransferase attaches RNA chains to host proteins. Nature 620, 1054–1062 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Suskiewicz M. J., Prokhorova E., Rack J. G. M., Ahel I., ADP-ribosylation from molecular mechanisms to therapeutic implications. Cell 186, 4475–4495 (2023). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Moss J., Jacobson M. K., Stanley S. J., Reversibility of arginine-specific mono(ADP-ribosyl)ation: Identification in erythrocytes of an ADP-ribose-L-arginine cleavage enzyme. Proc. Natl. Acad. Sci. U.S.A. 82, 5603–5607 (1985). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mashimo M., Kato J., Moss J., Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases. DNA Repair 23, 88–94 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rack J. G. M., et al. , (ADP-ribosyl)hydrolases: Structural basis for differential substrate recognition and inhibition. Cell Chem. Biol. 25, 1533–1546.e12 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.H. R. Bourne, ADP-ribosylating toxins and G proteins. Insights into signal transduction. Joel Moss and Martha Vaughan, Eds. American Society for Microbiology, Washington, DC, 1990. xviii, 567 pp. Science (New York, N.Y.) 250, 841–842 (1990). [DOI] [PubMed]
  • 10.Bullen N. P., et al. , An ADP-ribosyltransferase toxin kills bacterial cells by modifying structured non-coding RNAs. Mol. Cell 82, 3484–3498.e11 (2022). [DOI] [PubMed] [Google Scholar]
  • 11.Ting S. Y., et al. , Bifunctional immunity proteins protect bacteria against FtsZ-targeting ADP-ribosylating toxins. Cell 175, 1380–1392.e14 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Jurènas D., et al. , Salmonella antibacterial Rhs polymorphic toxin inhibits translation through ADP-ribosylation of EF-Tu P-loop. Nucleic Acids Res. 50, 13114–13127 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.LeRoux M., et al. , The DarTG toxin-antitoxin system provides phage defence by ADP-ribosylating viral DNA. Nat. Microbiol. 7, 1028–1040 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vassallo C. N., Doering C. R., Laub M. T., Anti-viral defence by an mRNA ADP-ribosyltransferase that blocks translation. Nature 636, 190–197 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Di Girolamo M., Fabrizio G., Overview of the mammalian ADP-ribosyl-transferases clostridia toxin-like (ARTCs) family. Biochem. Pharmacol. 167, 86–96 (2019). [DOI] [PubMed] [Google Scholar]
  • 16.Paone G., et al. , ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc. Natl. Acad. Sci. U.S.A. 99, 8231–8235 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Paone G., et al. , ADP-ribosyltransferase-specific modification of human neutrophil peptide-1*. J. Biol. Chem. 281, 17054–17060 (2006). [DOI] [PubMed] [Google Scholar]
  • 18.Fabrizio G., et al. , ARTC1-mediated ADP-ribosylation of GRP78/BiP: A new player in endoplasmic-reticulum stress responses. Cell. Mol. Life Sci. 72, 1209–1225 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Moss J., Yost D. A., Stanley S. J., Amino acid-specific ADP-ribosylation. J. Biol. Chem. 258, 6466–6470 (1983). [PubMed] [Google Scholar]
  • 20.Vyas S., et al. , Family-wide analysis of poly(ADP-ribose) polymerase activity. Nat. Commun. 5, 4426 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Glowacki G., et al. , The family of toxin-related ecto-ADP-ribosyltransferases in humans and the mouse. Protein Sci. A Publ. Protein Soc. 11, 1657–1670 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Weng B., Thompson W. C., Kim H. J., Levine R. L., Moss J., Modification of the ADP-ribosyltransferase and NAD glycohydrolase activities of a mammalian transferase (ADP-ribosyltransferase 5) by auto-ADP-ribosylation. J. Biol. Chem. 274, 31797–31803 (1999). [DOI] [PubMed] [Google Scholar]
  • 23.Groom D. P., Lopacinski A., Garforth S. J., Schramm V. L., Kinetic mechanism of the emergent anticancer target, human ADP-ribosyltransferase 1. Biochemistry 64, 2077–2088 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Ledford B. E., Leno G. H., ADP-ribosylation of the molecular chaperone GRP78/BiP. Mol. Cell. Biochem. 138, 141–148 (1994). [DOI] [PubMed] [Google Scholar]
  • 25.Laitusis A. L., Brostrom M. A., Brostrom C. O., The dynamic role of GRP78/BiP in the coordination of mRNA translation with protein processing*. J. Biol. Chem. 274, 486–493 (1999). [DOI] [PubMed] [Google Scholar]
  • 26.Adriouch S., et al. , S Adriouch, et al., ADP-ribosylation at R125 gates the P2X7 ion channel by presenting a covalent ligand to its nucleotide binding site: Offcial publication Fed. FASEB J.: Am. Soc. Exp. Biol. 22, 861–869 (2008). [DOI] [PubMed] [Google Scholar]
  • 27.Burnstock G., Knight G. E., Cellular distribution and functions of P2 receptor subtypes in different systems. Int. Rev. Cytol. 240, 31–304 (2004). [DOI] [PubMed] [Google Scholar]
  • 28.Wennerberg E., et al. , Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. Sci. Transl. Med. 14, eabe8195 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Adinolfi E., et al. , Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 75, 635–644 (2015). [DOI] [PubMed] [Google Scholar]
  • 30.Seman M., et al. , NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19, 571–582 (2003). [DOI] [PubMed] [Google Scholar]
  • 31.Adriouch S., et al. , NAD+ released during inflammation participates in T cell homeostasis by inducing ART2-mediated death of naive T cells in vivo1. J. Immunol. 179, 186–194 (2007). [DOI] [PubMed] [Google Scholar]
  • 32.B. Rissiek, F. Haag, O. Boyer, F. Koch-Nolte, S. Adriouch, “ADP-Ribosylation of P2X7: A matter of life and death for regulatory T cells and natural killer T cells” in Endogenous ADP-Ribosylation, F. Koch-Nolte, Ed. (Springer International Publishing, Cham, Switzerland, 2015), pp. 107–126. [DOI] [PubMed]
  • 33.Scheuplein F., et al. , NAD+ and ATP released from injured cells induce P2X7-dependent shedding of CD62L and externalization of phosphatidylserine by murine T cells. J. Immunol. 182, 2898–2908 (2009). [DOI] [PubMed] [Google Scholar]
  • 34.Audrito V., Messana V. G., Brandimarte L., Deaglio S., The extracellular NADome modulates immune responses. Front. Immunol. 12, 704779 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Gasparrini M., Sorci L., Raffaelli N., Enzymology of extracellular NAD metabolism. Cell. Mol. Life Sci. 78, 3317–3331 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lischke T., et al. , CD8-β ADP-ribosylation affects CD8(+) T-cell function. Eur. J. Immunol. 43, 1828–1838 (2013). [DOI] [PubMed] [Google Scholar]
  • 37.Lin T., et al. , ART1 knockdown decreases the IL-6-induced proliferation of colorectal cancer cells. BMC Cancer 24, 354 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Li Z., Yan X., Sun Y., Yang X., Expression of ADP-ribosyltransferase 1 is associated with poor prognosis of glioma patients. Tohoku J. Exp. Med. 239, 269–278 (2016). [DOI] [PubMed] [Google Scholar]
  • 39.Wu Z., Song S., Zhou J., Zhang Q., Yu J., Pan-cancer analysis of ART1 and its potential value in gastric cancer. J. Cancer 15, 3684–3707 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rising K. A., Schramm V. L., Transition state analysis of NAD+ hydrolysis by the cholera toxin catalytic subunit J. Am. Chem. Soc. 119, 27–37 (1997). [Google Scholar]
  • 41.Scheuring J., Schramm V. L., Kinetic isotope effect characterization of the transition state for oxidized nicotinamide adenine dinucleotide hydrolysis by pertussis toxin. Biochemistry 36, 4526–4534 (1997). [DOI] [PubMed] [Google Scholar]
  • 42.Berti P. J., Blanke S. R., Schramm V. L., Transition state structure for the hydrolysis of NAD+ catalyzed by diphtheria toxin. J. Am. Chem. Soc. 119, 12079–12088 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Scheuring J., Schramm V. L., Pertussis toxin: Transition state analysis for ADP-ribosylation of G-protein peptide α i3 C20. Biochemistry 36, 8215–8223 (1997b). [DOI] [PubMed] [Google Scholar]
  • 44.Scheuring J., Berti P. J., Schramm V. L., Transition-state structure for the ADP-ribosylation of recombinant G i α 1 subunits by pertussis toxin. Biochemistry 37, 2748–2758 (1998). [DOI] [PubMed] [Google Scholar]
  • 45.Parikh S. L., Schramm V. L., Transition state structure for ADP-ribosylation of eukaryotic elongation factor 2 catalyzed by diphtheria toxin. Biochemistry 43, 1204–1212 (2004). [DOI] [PubMed] [Google Scholar]
  • 46.Zhou G. C., et al. , Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states. J. Am. Chem. Soc. 126, 5690–5698 (2004). [DOI] [PubMed] [Google Scholar]
  • 47.Leutert M., et al. , Proteomic characterization of the heart and skeletal muscle reveals widespread arginine ADP-ribosylation by the ARTC1 ectoenzyme. Cell Rep. 24, 1916–1929.e5 (2018). [DOI] [PubMed] [Google Scholar]
  • 48.Cervantes-Laurean D., Minter D. E., Jacobson E. L., Jacobson M. K., Protein glycation by ADP-ribose: Studies of model conjugates. Biochemistry 32, 1528–1534 (1993). [DOI] [PubMed] [Google Scholar]
  • 49.Stevens L. A., Levine R. L., Gochuico B. R., Moss J., ADP-ribosylation of human defensin HNP-1 results in the replacement of the modified arginine with the noncoded amino acid ornithine. Proc. Natl. Acad. Sci. U.S.A. 106, 19796–19800 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rose I. A., The isotope trapping method: Desorption rates of productive E.S complexes. Methods Enzymol. 64, 47–59 (1980). [DOI] [PubMed] [Google Scholar]
  • 51.Sunko D. E., Szele I., Hehre W. J., Hyperconjugation and the angular dependence of beta-deuterium isotope effects. J. Am. Chem. Soc. 99, 5000–5005 (1977). [Google Scholar]
  • 52.Cen Y., Sauve A. A., Transition state of ADP-ribosylation of acetyllysine catalyzed by Archaeoglobus fulgidus Sir2 determined by kinetic isotope effects and computational approaches. J. Am. Chem. Soc. 132, 12286–12298 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Berti P. J., Schramm V. L., Transition state structure of the solvolytic hydrolysis of NAD+ J. Am. Chem. Soc. 119, 12069–12078 (1997). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Barrio J. R., Secrist J. A., Leonard N. J., A fluorescent analog of nicotinamide adenine dinucleotide. Proc. Natl. Acad. Sci. U.S.A. 69, 2039–2042 (1972). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Gadda G., Sobrado P., Kinetic solvent viscosity effects as probes for studying the mechanisms of enzyme action. Biochemistry 57, 3445–3453 (2018). [DOI] [PubMed] [Google Scholar]
  • 56.Fernandez P. L., Murkin A. S., Inverse solvent isotope effects in enzyme-catalyzed reactions. Molecules 25, 1933 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Abramson J., et al. , Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493–500 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Berti P. J., McCann J. A. B., Toward a detailed understanding of base excision repair enzymes: Transition state and mechanistic analyses of N-glycoside hydrolysis and N-glycoside transfer. Chem. Rev. 106, 506–555 (2006). [DOI] [PubMed] [Google Scholar]
  • 59.Schramm V. L., Enzymatic transition states and drug design. Chem. Rev. 118, 11194–11258 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Takada T., Iida K., Moss J., Conservation of a common motif in enzymes catalyzing ADP-ribose transfer: Identification of domains in mammalian transferases (*). J. Biol. Chem. 270, 541–544 (1995). [DOI] [PubMed] [Google Scholar]
  • 61.Lobet Y., Cluff C. W., Cieplak W., Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin. Infect. Immun. 59, 2870–2879 (1991). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Douglas C. M., Collier R. J., Exotoxin A of Pseudomonas aeruginosa: Substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J. Bacteriol. 169, 4967–4971 (1987). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Cieplak W., Mead D. J., Messer R. J., Grant C. C. R., Site-directed mutagenic alteration of potential active-site residues of the A subunit of Escherichia coli heat-labile enterotoxin: Evidence for a catalytic role for glutamic acid 112 (*). J. Biol. Chem. 270, 30545–30550 (1995). [DOI] [PubMed] [Google Scholar]
  • 64.Hara N., Tsuchiya M., Shimoyama M., Glutamic acid 207 in rodent T-cell RT6 antigens is essential for arginine-specific ADP-ribosylation*. J. Biol. Chem. 271, 29552–29555 (1996). [DOI] [PubMed] [Google Scholar]
  • 65.Rust H. L., Zurita-Lopez C. I., Clarke S., Thompson P. R., Mechanistic studies on transcriptional coactivator protein arginine methyltransferase 1. Biochemistry 50, 3332–3345 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Zhang R., et al. , Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1. PLoS ONE 8, e72424 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Piniello B., García-García A., Pietrucci F., Hurtado-Guerrero R., Rovira C., Mechanism of bacterial arginine N-glycosylation: A chemically challenging post-translational modification. ACS Catal. 16, 2550–2562 (2026). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Ren W. S., et al. , Catalytic mechanism and product specificity of protein arginine methyltransferase PRMT7: A study from QM/MM molecular dynamics and free energy simulations. J. Chem. Theory Comput. 16, 5301–5312 (2020). [DOI] [PubMed] [Google Scholar]
  • 69.Park J. B., et al. , Structural basis for arginine glycosylation of host substrates by bacterial effector proteins. Nat. Commun. 9, 4283 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Ding J., et al. , Structural and functional insights into host death domains inactivation by the bacterial arginine GlcNAcyltransferase effector. Mol. Cell 74, 922–935.e6 (2019). [DOI] [PubMed] [Google Scholar]
  • 71.Zhu C., et al. , Tautomerization-dependent recognition and excision of oxidation damage in base-excision DNA repair. Proc. Natl. Acad. Sci. U.S.A. 113, 7792–7797 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Sadeghian K., Ochsenfeld C., Unraveling the base excision repair mechanism of human DNA glycosylase. J. Am. Chem. Soc. 137, 9824–9831 (2015). [DOI] [PubMed] [Google Scholar]
  • 73.Unno M., et al. , Capturing a glycosylase reaction intermediate in DNA repair by freeze-trapping of a pH-responsive hOGG1 mutant. Nucleic Acids Res. 53, gkaf718 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Banasik M., Komura H., Shimoyama M., Ueda K., Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. 267, 1569–1575 (1992). [PubMed] [Google Scholar]
  • 75.Burgos E. S., Vetticatt M. J., Schramm V. L., Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase. J. Am. Chem. Soc. 135, 3485–3493 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Ghosh A. K., Groom D. P., Schramm V. L., Transition state analysis of SAMHD1 from primary 18O, 33P, and solvent kinetic isotope effects. J. Am. Chem. Soc. 147, 8852–8863 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.M. J. Frisch et al., Gaussian 16 Rev. C.01 (Gaussian Inc. Wallingford CT, 2016).
  • 78.Anisimov V., Paneth P., ISOEFF98., A program for studies of isotope effects using Hessian modifications. J. Math. Chem. 26, 75–86 (1999). [Google Scholar]
  • 79.V. Anisinov, P. Paneth, “ISOEFF07” (Technical University of Lodz, Lodz, Poland, 2007).
  • 80.Schrödinger, LLC, The PyMOL molecular graphics system, version 1.8 (Schrödinger, LLC, 2015).
  • 81.The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025. UniProt. https://www.uniprot.org/uniprotkb/P52961/. Deposited 28 January 2026.
  • 82.The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025. UniProt. https://www.uniprot.org/uniprotkb/Q99572/. Deposited 28 January 2026.
  • 83.The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025. UniProt. https://www.uniprot.org/uniprotkb/P54922/. Deposited 28 January 2026.
  • 84.The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025. UniProt. https://www.uniprot.org/uniprotkb/Q9UKK9/. Deposited 28 January 2026.
  • 85.The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025. UniProt. https://www.uniprot.org/uniprotkb/P22983/. Deposited 28 January 2026.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Appendix 01 (PDF)

Data Availability Statement

Accession Codes: hsART1 (UniProt: P52961) (81), hsP2X7 (Uniprot: Q99572) (82), hsARH1 (UniProt: P54922) (83), hsNUDIX5 (UniProt: Q9UKK9) (84), and CsPPDK (UniProt: P22983) (85). All other data are included in the manuscript and/or SI Appendix.


Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES